Adverum Biotechnologies, Inc. (ADVM)
Dec 9, 2025 - ADVM was delisted (reason: acquired by LLY)
4.360
+0.100 (2.35%)
Inactive · Last trade price on Dec 8, 2025
Adverum Biotechnologies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 26.06 | 60.65 | 75 | 68.43 | 34.2 | 62.42 |
Short-Term Investments | - | 65.04 | 21.53 | 117.16 | 270.99 | 367.31 |
Cash & Short-Term Investments | 26.06 | 125.69 | 96.53 | 185.59 | 305.19 | 429.73 |
Cash Growth | -82.99% | 30.21% | -47.99% | -39.19% | -28.98% | 158.82% |
Other Receivables | - | - | - | - | 5.71 | - |
Total Trade Receivables | - | - | - | - | 5.71 | - |
Other Current Assets | 2.85 | 5.61 | 6.25 | 5.01 | 6.25 | 4.71 |
Total Current Assets | 28.91 | 131.3 | 102.77 | 190.6 | 317.15 | 434.44 |
Net Property, Plant & Equipment | 39.49 | 45.22 | 49.79 | 113.86 | 119.06 | 47.1 |
Other Long-Term Assets | 4 | 3.32 | 3.21 | 3.92 | 3.52 | 1.03 |
Total Assets | 72.4 | 179.84 | 155.77 | 308.37 | 439.73 | 482.57 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 12.46 | 1.61 | 1.92 | 2.24 | 1.39 | 2.81 |
Accrued Expenses | 26.48 | 15.62 | 12.58 | 16.77 | 18.05 | 13.59 |
Current Portion of Leases | 5.81 | 5.67 | 5.48 | 13.24 | 1.89 | 4.47 |
Total Current Liabilities | 44.75 | 22.9 | 19.98 | 32.25 | 21.32 | 20.87 |
Long-Term Leases | 83.13 | 86.04 | 68.57 | 93.56 | 101.11 | 26.24 |
Other Long-Term Liabilities | 0.18 | 0.19 | - | 1.05 | 1.11 | 1.11 |
Total Long-Term Liabilities | 83.31 | 86.23 | 68.57 | 94.61 | 102.22 | 27.35 |
Total Liabilities | 128.05 | 109.13 | 88.55 | 126.85 | 123.54 | 48.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,156 | 1,138 | 1,004 | 985.65 | 964.97 | 937.13 |
Accumulated Other Comprehensive Income | -0.44 | -0.81 | -0.47 | -1.53 | -0.71 | -0.26 |
Retained Earnings | -1,211 | -1,067 | -936.02 | -802.61 | -648.08 | -502.54 |
Shareholders' Equity | -55.65 | 70.71 | 67.22 | 181.52 | 316.19 | 434.35 |
Total Liabilities & Equity | 72.4 | 179.84 | 155.77 | 308.37 | 439.73 | 482.57 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 88.94 | 91.71 | 74.04 | 106.8 | 102.99 | 30.71 |
Net Cash (Debt) | -62.88 | 33.99 | 22.49 | 78.79 | 202.19 | 399.02 |
Net Cash Growth | - | 51.15% | -71.46% | -61.03% | -49.33% | 198.25% |
Net Cash Per Share | -2.91 | 1.72 | 2.23 | 7.94 | 20.62 | 46.86 |
Book Value | -55.65 | 70.71 | 67.22 | 181.52 | 316.19 | 434.35 |
Book Value Per Share | -2.58 | 3.57 | 6.67 | 18.29 | 32.25 | 51.01 |
Tangible Book Value | -55.65 | 70.71 | 67.22 | 181.52 | 316.19 | 434.35 |
Tangible Book Value Per Share | -2.58 | 3.57 | 6.67 | 18.29 | 32.25 | 51.01 |